Here we present a rationale for indirect epigenetic and downstream inhibition of MYC signaling together with TMZ as a potential therapeutic strategy for a subset of proneural GBM that presents a specific sensitivity expression signature. The gene discussed is MYC; the disease is glioblastoma.